MMTec, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTC research report →
Price Chart
About the company
MMTec, Inc. , together with its subsidiaries, develops and deploys platforms that enable financial institutions to engage in securities market transactions and settlements worldwide. It operates in two segments: Gujia, MM Future, HC Securities; and MM Global.
- CEO
- Xiang Dong Wen
- IPO
- 2019
- Employees
- 31
- HQ
- Hong Kong, HK
Get TickerSpark's AI analysis on MTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $129.08M
- P/E
- -20.04
- PEG
- -0.11
- P/S
- 0.00
- P/B
- 39.37
- EV/EBITDA
- -34.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -81.68%
- ROIC
- -20.82%
Latest fiscal year · YoY change
- Revenue
- $-20,484,930-1196.4%
- Gross Profit
- $-21,285,786-1586.7%
- Op Income
- $-48,981,994
- Net Income
- $-56,075,245+38.5%
- EPS
- $-1.05+71.2%
- OCF Growth
- -611.0%
- FCF Growth
- -614.6%
- 52W High
- $9.10
- 52W Low
- $0.25
- 50D MA
- $4.23
- 200D MA
- $4.38
- Beta
- -0.16
- RSI (14)
- 52
- Avg Volume
- 25.90K
No earnings-call transcripts are available for MTC yet.
- Free Float
- 99.8%
- Shares Outstanding
- 25.19M
- Float Shares
- 25.14M
of shares held by institutions
5 13F filers
Held by 3 ETFs
Biggest fund positions in MTC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Ren Xiaofei | other | 0 |
| Mar 18, 26 | Wen Xiangdong | other | 0 |
| Mar 18, 26 | Wen Xiangdong | other | 0 |
| Mar 18, 26 | Meng Qingshun | other | 0 |
| Mar 18, 26 | Kong Min | other | 0 |
| Mar 18, 26 | Fu Dan | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MTC coverage
Recent articles, reports, and earnings notes.
No research on MTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MTC report →Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
gurufocus.com · Sep 30
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
gurufocus.com · Sep 29
Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform
businesswire.com · Jun 23
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
gurufocus.com · Jun 7
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
gurufocus.com · Jun 6
MMTec (NASDAQ:MTC) Stock Price Down 6.9% – Time to Sell?
defenseworld.net · Jan 6
MMTEC, Inc. Announces Receipt of Nasdaq Decision Regarding Minimum Bid Price Deficiency
prnewswire.com · Dec 11
MMTEC, Inc. Announces Receipt of Nasdaq Delisting Determination Regarding Minimum Bid Price Deficiency
prnewswire.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.